Cortical dopaminergic system (CDS)

The cortical dopaminergic system refers to the network of dopaminergic projections originating in the ventral tegmental area (VTA) and terminating in various regions of the cerebral cortex, most notably the prefrontal cortex. This system, often identified as the mesocortical pathway, is essential for higher-order cognitive processes including working memory, executive function, and emotional regulation. Unlike the subcortical striatal regions where the dopamine transporter (DAT) is abundant, dopamine clearance in the cortex relies heavily on the norepinephrine transporter (NET) and enzymatic degradation by catechol-O-methyltransferase (COMT). Dysfunction of the cortical dopaminergic system is a hallmark of several neuropsychiatric disorders. In schizophrenia, a deficit in cortical dopamine (hypodopaminergia) is hypothesized to underlie negative symptoms and cognitive deficits, while in ADHD, dysregulation of this system contributes to inattention and impulsivity. Pharmacological intervention often aims to enhance cortical dopaminergic tone using stimulants or atypical antipsychotics that possess 5-HT2A antagonism, which can disinhibit dopamine release in the frontal lobes. Because it is a complex physiological pathway involving multiple receptors (D1-D5) and transporters rather than a single protein, it is classified as a system rather than a discrete molecular target.

Other names

Mesocortical pathwayMesocortical dopaminergic pathwayCortical dopamine system

Drugs typically modulate this system by acting as agonists or antagonists at dopamine receptors (D1, D2, D4) or by inhibiting the reuptake of dopamine and norepinephrine via transporters (DAT, NET) to restore balanced cortical signaling.